Secondary HLH in an Adult: The Best-Proven Regimen Against the Gentler One
A single patient, critically ill with an already-suppressed marrow. The disagreement isn't whether he needs urgent therapy — it's whether the best-proven regimen is still the right one once his own marrow reserve is factored in.
Frank L. had settled into a comfortable retirement routine of morning walks with a group of neighbors and afternoon crossword puzzles at the same coffee shop, two years removed from thirty years with the postal service, before a persistent fever sent him to the emergency department after ten days of feeling progressively worse — drenching night sweats, a fifteen-pound weight loss he hadn't been trying for, and a fatigue severe enough that his walking group noticed before he complained of it himself. On exam he has a palpable spleen tip four centimeters below the costal margin and mild scleral icterus.
His workup found hepatosplenomegaly on imaging, pancytopenia with a hemoglobin of 7.8 and platelets of 41,000, a ferritin over 12,000, fibrinogen under 100, and a markedly elevated soluble IL-2 receptor level — a constellation that met diagnostic criteria for hemophagocytic lymphohistiocytosis on the standard HLH-2004 criteria, with a bone marrow biopsy showing hemophagocytosis directly and subsequent EBV PCR testing identifying an underlying EBV-driven trigger rather than a primary genetic HLH syndrome, which his age alone already made unlikely.
HLH-94, the etoposide-and-dexamethasone protocol that remains the most extensively validated regimen across HLH's various causes, carries real survival data spanning three decades — but it was developed and validated primarily in children, and etoposide's myelosuppression is a materially different proposition in a 63-year-old whose marrow is already suppressed by the disease itself. Ruxolitinib, a JAK1/2 inhibitor, has accumulated a growing body of real-world and small prospective evidence specifically in secondary and malignancy-associated HLH in adults, with a gentler marrow-toxicity profile than etoposide-based chemotherapy — though its evidence base remains far thinner than HLH-94's, built mostly from case series and single-arm studies rather than randomized comparison.
The best-proven regimen against the gentler one
HLH-94 has the deepest and longest-validated survival data of any regimen across HLH's causes, and I don't think we should reach past the best-evidenced option for something newer just because he's an adult. Etoposide and dexamethasone, dosed per protocol, is where I'd start.
I'd want his marrow reserve watched closely given his age and already-present pancytopenia — that's a real, named risk, not a reason to abandon the regimen with the strongest outcomes data behind it.
I take the survival-data point seriously, but his marrow is already suppressed by the disease itself before etoposide is even given — adding a myelosuppressive chemotherapeutic agent on top of that, in a 63-year-old, risks compounding the very cytopenias driving his critical illness. Ruxolitinib's growing evidence base in secondary and malignancy-associated HLH, with a meaningfully gentler marrow-toxicity profile, is a real alternative worth weighing seriously here, not just in refractory cases.
I want to be honest that this evidence base is real but thinner — case series and single-arm data, not a randomized trial against HLH-94. This is a genuine trade-off, not a clearly superior option.
Agreed: start a dose-modified HLH-94 regimen with reduced-intensity etoposide dosing given his age and existing pancytopenia, plus rituximab for his identified EBV trigger.
Not agreed: at what point a poor early response should prompt a switch toward ruxolitinib rather than intensifying the existing protocol — genuinely left open given how thin the head-to-head evidence actually is, rather than resolved by either voice claiming certainty it didn't have.